Pandemic or not, we’re here to serve you, whatever your eye care need may be. Learn about our COVID-19 safety precautions.
Dr. Ahmad Fahmy is the Director of Optometric Services at Minnesota Eye Consultants. He received his professional training and the Doctor of Optometry degree in 2001 from the Illinois College of Optometry. He completed residency training in the perioperative care of glaucoma, anterior segment pathology, and refractive surgery with Minnesota Eye Consultants, P.A. in 2004. He earned Fellowship in the American Academy of Optometry in 2004 and joined Minnesota Eye Consultants, P.A. as a staff optometrist also in 2004.
He earned Diplomate designation in the American Board of Optometry in 2014. Dr. Fahmy is an Adjunct Faculty Assistant Professor of the Illinois College of Optometry, and Southern California College of Optometry.
Dr. Fahmy is a devoted advocate of an integrated eye care delivery model and serves as a member of the American Society of Cataract and Refractive Surgery’s Integrated Practice Committee (IPC).
He is an editorial board peer reviewer for the journal Clinical Ophthalmology. He is a member of the American Academy of Optometry, American Optometric Association, Minnesota Optometric Association, Volunteer Optometric Services to Humanity, and the Optometric Council of Refractive Surgery. He has contributed to book chapters, journal articles, and case studies in non-peer reviewed and peer-reviewed journals including Optometry Times, Ophthalmology Times Europe, Archives of Ophthalmology, and The Journal of Cataract and Refractive Surgery. He has lectured at educational conferences including the American Academy of Optometry, Minnesota Optometric Association, The Philips Eye Institute, and International Congress in Lima, Peru.
He has been involved in the clinical care of disadvantaged populations and is devoted to continued involvement in the development of philanthropic eye care initiatives. He also remains committed to teaching and mentoring. He is actively involved in numerous clinical research trials and has a special interest in the ocular surface disease.